Recently, 68Ga-magnetic iron oxide nanoparticles targeting PSMA and gastrin-releasing peptide receptors (GRPRs) have been developed as a potential tool for PET/MRI diagnosis of PCa and are thought to improve the efficacy of PCa-targeted therapy, but further application in mouse models is needed [128]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.